Over the last year, diabetes technology saw significant changes: acceleration of patch pumps, ever-smaller continuous glucose monitors, implanted CGMs and increased interest in devices that measure additional chemicals in blood without needles. On the structural side, Medtronic plc announced plans to split off its diabetes unit as a public company and a number of partnerships brought the technology ever closer to an external artificial pancreas. What's on the horizon for 2026?

GLP-1s are hot, but med tech still has a seat at the obesity table

Sustaining healthy weight loss is about much more than cutting calories or injecting drugs, as many GLP-1 users are discovering. Widely seen as miracle drugs, semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Zepbound, Mounjaro) and related medications have transformed the treatment of obesity and diabetes and apparently lessened the need for medical device intervention in many instances. However, many patients will still need surgical intervention to achieve their weight loss goals.

Nia reports promising results for Smart Neurostimulation System

Nia Therapeutics Inc. reported data from an in vivo study of its Smart Neurostimulation System, an AI-based brain-computer interface (BCI), which demonstrated its ability to perform chronic sensing, neural-state decoding and programmable stimulation. Nia is preparing for first-in-human studies joining a growing number of companies conducting clinical trials of their BCI system as they look to transform the lives of people with neurological conditions.

UK’s NICE revisiting thresholds and care pathways for ovarian cancer

The U.K. National Institute for Health and Care Excellence (NICE) has posted a draft update on its recommendations for ovarian cancer testing, suggesting that the existing thresholds for cancer antigen 125 be modified. NICE is considering lowering the existing threshold for this antigen for some women, a change that may mean that patients will be referred more quickly for suspected ovarian cancer.

TGA eyes do-over for conformity assessment procedures

Australia’s Therapeutic Goods Administration posted a proposed rework of the agency’s conformity assessment procedures in a move that would align Australia’s regulations more closely to those in the EU. However, the agency acknowledged that a five-year device recertification schedule is often a low-value diversion of resources needed in other areas, not unlike the predicament in the EU.

Med-tech gainers and losers for Dec. 29, 2025-Jan. 2, 2026

The top 10 med-tech stock gainers and losers for the week.

Also in the news

Accendra Health, Brainspace, Ceribell, Inspira, Intelligent Bio Solutions, Intelligent Scopes, Lantheus, Naox Technologies, Orasure, Setpoint, Shine, W.L. Gore